Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Furosemide and Coarctation Surgery Lung Complications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03364842
Recruitment Status : Completed
First Posted : December 7, 2017
Last Update Posted : December 27, 2017
Sponsor:
Information provided by (Responsible Party):
Ahmed Kareem, Cairo University

Brief Summary:
in our study the investigators give furosemide during surgery for repair of aortic coarctation via lateral thoracotomy and evaluated lung complications in comparison to control group

Condition or disease Intervention/treatment Phase
Pulmonary Complication Drug: Furosemide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Supportive Care
Official Title: Furosemide: Would it Help to Improve the Lungs During Aortic Coarctation Surgery
Actual Study Start Date : November 22, 2017
Actual Primary Completion Date : December 20, 2017
Actual Study Completion Date : December 20, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Furosemide

Arm Intervention/treatment
Experimental: F group
Furosemide group
Drug: Furosemide
Administering furosemide

No Intervention: C group
Control group



Primary Outcome Measures :
  1. lung ultrasonography scale > 24 [ Time Frame: a 1 year study ]

Secondary Outcome Measures :
  1. Pao2/ Fio2 ratio [ Time Frame: a 1 year study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 18 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • coarctation of aorta

Exclusion Criteria:

  • heart failure, bleeding diathesis, associated cardiac congenital anomalies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364842


Locations
Layout table for location information
Egypt
Cairo university
Cairo, Egypt
Sponsors and Collaborators
Cairo University

Layout table for additonal information
Responsible Party: Ahmed Kareem, Principal investigator, Cairo University
ClinicalTrials.gov Identifier: NCT03364842     History of Changes
Other Study ID Numbers: Fuurosemide and coarctation
First Posted: December 7, 2017    Key Record Dates
Last Update Posted: December 27, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Furosemide
Aortic Coarctation
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action